Home > Drugs A – Z > Eszopiclone (By mouth)

Eszopiclone (By mouth)

Treats insomnia.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Eszopiclone is used to treat insomnia (trouble sleeping). It belongs to the group of medicines called central nervous system (CNS) depressants, which are medicines that slow down the nervous system. Eszopiclone helps you get to sleep faster and sleep through the night. This medicine is available only with your doctor's prescription… Read more
Brand names include
Lunesta
Drug classes About this
Nonbarbiturate Hypnotic

What works? Research summarized

Evidence reviews

Eszopiclone for insomnia

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy data, and adverse effects of eszopiclone in the treatment of transient and chronic insomnia in adult and geriatric patients.

Drug Class Review: Newer Drugs for Insomnia: Final Report Update 2 [Internet]

Insomnia is a serious health problem that affects millions of people. Population surveys have estimated the prevalence of insomnia to be about 30% to 50% of the general population. About three-fourths of people who have trouble sleeping say that the problem is "occasional," averaging about 6 nights per month, with one-fourth having frequent or chronic insomnia, averaging about 16 nights per month. Individuals with insomnia most often report a combination of difficulty falling asleep and intermittent wakefulness during sleep. Treatment of insomnia involves behavioral changes, such as minimizing habits that interfere with sleep (for example, drinking coffee or engaging in stressful activities in the evening), and pharmacotherapy with sedating antidepressants (for example, trazodone), sedating antihistamines, anticholinergics, benzodiazepines, or nonbenzodiazepine hypnotics. The benzodiazepines and the newer sedative hypnotics zolpidem, zaleplon, zopiclone, and eszopiclone work through gamma-aminobutyric acid receptors. Ramelteon, a hypnotic approved by the United States Food and Drug Administration (FDA) in July 2005, is a selective melatonin receptor (MT1 and MT2) agonist. New nonbenzodiazepine drugs have been sought for multiple reasons, including reduction of the risk of tolerance, dependence, and abuse associated with benzodiazepines. The purpose of this review is to evaluate the comparative evidence on benefits and harms of these medications in people with insomnia to help policymakers and clinicians make informed choices about the use of newer drugs for insomnia.

Dementia: A NICE-SCIE Guideline on Supporting People With Dementia and Their Carers in Health and Social Care

This guideline has been developed to advise on supporting people with dementia and their carers in health and social care. The guideline recommendations have been developed by a multidisciplinary team of health and social care professionals, a person with dementia, carers and guideline methodologists after careful consideration of the best available evidence. It is intended that the guideline will be useful to practitioners and service commissioners in providing and planning high-quality care for those with dementia while also emphasising the importance of the experience of care for people with dementia and carers.

See all (11)

Summaries for consumers

Comparing Newer Drugs for Insomnia

How do newer drugs compare in the treatment of insomnia?

Effects of opioid, hypnotic and sedating medications on obstructive sleep apnoea (OSA) in adults with known OSA

Obstructive sleep apnoea (OSA) is a common sleep disorder characterised by intermittent apnoeas (pauses in breathing) leading to dips in oxygen levels in the blood during sleep. Many people with known or unknown (undiagnosed) OSA receive hypnotics, sedatives and opiate/opioid drugs to treat other conditions including pain, anxiety and difficulty sleeping. Opiates/opioids are commonly prescribed to treat pain after major surgery. These drugs might make sleep apnoea worse ‐ increasing the frequency and duration of apnoeas.

Drug therapy for obstructive sleep apnoea in adults

Obstructive sleep apnoea (OSA) is caused by collapse of the upper airway. The mainstay of medical treatment is continuous positive airways pressure (CPAP), delivered through a mask during sleep, aiming to keep the airway opened. Drug therapy has been proposed for individuals with mild OSA and those intolerant of CPAP.

PubMed Health Blog...

read all...